Challenges of Using Sodium-Glucose Transporter-2 (Sglt-2) Inhibitors in the Treatment of Gestational Diabetes and Its Safety Considerations During Pregnancy

Challenges of Using Sodium-Glucose Transporter-2 (Sglt-2) Inhibitors in the Treatment of Gestational Diabetes and Its Safety Considerations During Pregnancy

Bandarian M¹ ; Bandarian F^{2, 3}

Show Affiliations

1. Department of Obstetrics and Gynecology, Ziaeian Hospital, Tehran University of Medical Sciences, Tehran, Iran
2. Metabolomics and Genomics Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
3. Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

Source: Iranian Journal of Diabetes and Metabolism Published:2023

Abstract

Sodium-glucose transporter-2 (SGLT-2) inhibitors are a relatively new class of anti-diabetic drugs with potent effect in glycemic control and weight loss, as well as beneficial effects in the prevention and control of cardiac and renal complications in non-pregnant patients with type 2 diabetes. However, there is no enough clear and strong evidence about the beneficial or adverse effect of SGLT-2 inhibitors usage during pregnancy for management of gestational diabetes (GDM) in human. This short letter discusses challenges in application of SGLT-2 inhibitors in management of GDM. © 2023, Tehran University of Medical Sciences. All rights reserved.

Style	Citing Format
MLA	Bandarian M, Bandarian F. "Challenges of Using Sodium-Glucose Transporter-2 (Sglt-2) Inhibitors in the Treatment of Gestational Diabetes and Its Safety Considerations During Pregnancy." Iranian Journal of Diabetes and Metabolism, vol. 23, no. 5, 2023, pp. 270-272.
APA	Bandarian M, Bandarian F (2023). Challenges of Using Sodium-Glucose Transporter-2 (Sglt-2) Inhibitors in the Treatment of Gestational Diabetes and Its Safety Considerations During Pregnancy. Iranian Journal of Diabetes and Metabolism, 23(5), 270-272.
Chicago	Bandarian M, Bandarian F. "Challenges of Using Sodium-Glucose Transporter-2 (Sglt-2) Inhibitors in the Treatment of Gestational Diabetes and Its Safety Considerations During Pregnancy." Iranian Journal of Diabetes and Metabolism 23, no. 5 (2023): 270-272.
Harvard	Bandarian M, Bandarian F (2023) 'Challenges of Using Sodium-Glucose Transporter-2 (Sglt-2) Inhibitors in the Treatment of Gestational Diabetes and Its Safety Considerations During Pregnancy', Iranian Journal of Diabetes and Metabolism, 23(5), pp. 270-272.
Vancouver	Bandarian M, Bandarian F. Challenges of Using Sodium-Glucose Transporter-2 (Sglt-2) Inhibitors in the Treatment of Gestational Diabetes and Its Safety Considerations During Pregnancy. Iranian Journal of Diabetes and Metabolism. 2023;23(5):270-272.
BibTex	@article{ author = {Bandarian M and Bandarian F}, title = {Challenges of Using Sodium-Glucose Transporter-2 (Sglt-2) Inhibitors in the Treatment of Gestational Diabetes and Its Safety Considerations During Pregnancy}, journal = {Iranian Journal of Diabetes and Metabolism}, volume = {23}, number = {5}, pages = {270-272}, year = {2023} }
RIS	TY - JOUR AU - Bandarian M AU - Bandarian F TI - Challenges of Using Sodium-Glucose Transporter-2 (Sglt-2) Inhibitors in the Treatment of Gestational Diabetes and Its Safety Considerations During Pregnancy JO - Iranian Journal of Diabetes and Metabolism VL - 23 IS - 5 SP - 270 EP - 272 PY - 2023 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract